US Urges Court to Toss AstraZeneca’s Drug Price Negotiation Suit

The Centers for Medicare & Medicaid Services is asking a federal court to dismiss AstraZeneca Plc’s challenge against a government drug price negotiation program, arguing a Biden-era law bars judicial review of the issue.

As a threshold matter, the US District Court for the District of Maryland “lacks statutory subject-matter jurisdiction over this suit,” the Department of Justice, representing the CMS, said in a March 27 motion.

“Both the plain text of the IRA and case law analyzing similar bars to judicial review in other parts of the Medicare statute confirm that this Court cannot ignore Congress’s choice ...